Vinorelbine derivatives
AssigneeAMR Technology, Inc.
InventorsIan SCOTT, Jeffrey RALPH, Matthew VOSS
Life of this patent
Estimating the term…
Abstract
The present invention relates to novel vinorelbine derivatives. Pharmaceutical compositions containing these compounds as well as processes of preparation and processes of use for treatment of various conditions are also disclosed.
Claims44
A method for inhibiting cell proliferation in mammals comprising:
- administering to the mammal a therapeutically effective amount of a compound of Formula (I) as follows:
- where:
- R1 is:
- alkyl;
- alkenyl;
- alkynyl;
- aryl;
- heterocyclyl;
- halogen;
- CN;
- CH(O);
- COR5;
- SO2NHNH2;
- SO2NR5NH2;
- SO2NR5NHR6;
- SO2NR5NR6R7;
- SO2NHNHR5;
- SO2NHNR5R6;
- CO2R5;
- SR5;
- SSR5;
- SOR5;
- SO2R5;
- SO2NHR5;
- SO2NR5R6;
- B(OR5)2;
- CF3;
- SH;
- SO2NH2;
- NH2;
- NHR5;
- NHCOR5;
- NHSO2R5;
- NR5R6;
- NR5COR6;
- or
- NR5SO2R6;
- R5 and R6 can form a ring;
- R2=alkyl or CH(O);
- R3=hydrogen, alkyl, or C(O)R5;
- R4=hydrogen or C(O)R5;
- R5 and R6 each are independently alkyl, alkenyl, alkynyl, aryl, or heterocyclyl;
- X=OR5, NR5R6, NHNH2, NHNHC(O)R5, OH, NHR5, NH2, or NHNHC(O)H;
- R4 and X may be linked together with intervening atoms to form a ring;
- or a pharmaceutically acceptable salt thereof, wherein the alkyl and alkenyl groups may be branched, straight, unsubstituted, and/or substituted and wherein the aryl, alkynyl, and heterocyclyl groups are substituted or unsubstituted.
A method for treating a condition in mammals selected from the group consisting of bacterial infection, allergy, heart disease, AIDS, Human T-lymphotropic virus 1 infection, Human herpesvirus 3, Human herpesvirus 4, Human papillomavirus, diabetes mellitus, rheumatoid arthritis, Alzheimer's Disease, inflammation, arthritis, asthma, malaria, autoimmune disease, eczema, Lupus erythematosus, psoriasis, rheumatic diseases, Sjogren's syndrome, and viral infection, said method comprising
- administering to the mammal a therapeutically effective amount of the compound of Formula (I) as follows:
- where:
- R1 is:
- alkyl;
- alkenyl;
- alkynyl;
- aryl;
- heterocyclyl;
- halogen;
- CN;
- CH(O);
- COR5;
- SO2NHNH2;
- SO2NR5NH2;
- SO2NR5NHR6;
- SO2NR5NR6R7;
- SO2NHNHR5;
- SO2NHNR5R6;
- CO2R5;
- SR5;
- SSR5;
- SOR5;
- SO2R5;
- SO2NHR5;
- SO2NR5R6;
- B(OR5)2;
- CF3;
- SH;
- SO2NH2;
- NH2;
- NHR5;
- NHCOR5;
- NHSO2R5;
- NR5R6;
- NR5COR6;
- or
- NR5SO2R6;
- R5 and R6 can form a ring;
- R2=alkyl or CH(O);
- R3=hydrogen, alkyl, or C(O)R5;
- R4=hydrogen or C(O)R5;
- R5 and R6 each are independently alkyl, alkenyl, alkynyl, aryl, or heterocyclyl;
- X=OR5, NR5R6, NHNH2, NHNHC(O)R5, OH, NHR5, NH2, or NHNHC(O)H;
- R4 and X may be linked together with intervening atoms to form a ring;
- or a pharmaceutically acceptable salt thereof, wherein the alkyl and alkenyl groups may be branched, straight, unsubstituted, and/or substituted and wherein the aryl, alkynyl, and heterocyclyl groups are substituted or unsubstituted.
Dependencies are inferred from the claim text.